

1 Article

# 2 Non-homologous end joining factors XLF, PAXX and 3 DNA-PKcs support neural stem and progenitor cells 4 development

5 Raquel Gago-Fuentes<sup>1,2</sup>, and Valentyn Oksenysh<sup>1,3,4,\*</sup>

6 <sup>1</sup> Department for Cancer Research and Molecular Medicine (IKOM), Norwegian University of Science and  
7 Technology, Laboratory Center, Erling Skjalgssons gate 1, 7491 Trondheim, Norway;

8 <sup>2</sup> Department of Circulation and Medical Imaging, Norwegian University of Science and Technology,  
9 Prinsesse Kristinas gate 3, Akkuten og Hjertelunge-senteret, Postboks 8905, 7491 Trondheim, Norway;

10 <sup>3</sup> KG Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, N-0316 Oslo,  
11 Norway;

12 <sup>4</sup> Institute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway; valentyn.oksenych@medisin.uio.no

13 \* Correspondence: valentyn.oksenych@medisin.uio.no (V.O.)

14 Received: date; Accepted: date; Published: date

15 **Abstract:** Non-homologous end-joining (NHEJ) is a major DNA repair pathway in mammalian cells  
16 that recognizes, processes and fixes DNA damages throughout the cell cycle, and is specifically  
17 important for homeostasis of post-mitotic neurons and developing lymphocytes. Neuronal  
18 apoptosis increases in the mice lacking core NHEJ factors Ku70 and Ku80. Inactivation of other core  
19 NHEJ genes, either Xrcc4 or Lig4, leads to massive neuronal apoptosis in the central nervous system  
20 (CNS) that correlates with embryonic lethality in mice. Inactivation of one accessory NHEJ gene,  
21 e.g. Paxx, Mri and Dna-pkcs, results in normal CNS development due to compensatory effects of  
22 Xlf. Combined inactivation of Xlf/Paxx, Xlf/Mri and Xlf/Dna-pkcs, however, results in late  
23 embryonic lethality and high levels of apoptosis in CNS. To determine the impact of accessory NHEJ  
24 on early stages of neurodevelopment, we isolated neural stem and progenitors cells from mouse  
25 embryos and investigated proliferation, self-renewal and differentiation capacity of these cells  
26 lacking either Xlf, Paxx, Dna-pkcs, Xlf/Paxx or Xlf/Dna-pkcs. We found that accessory NHEJ factors  
27 are important for maintaining the neural stem and progenitor cell populations and  
28 neurodevelopment in mammals, which is particularly evident in the double knockout models.

29 **Keywords:** DNA repair; NHEJ; synthetic lethality; genetic interaction

## 30 1. Introduction

31 Double-strand DNA breaks (DSBs) are common DNA damage events that threaten the stability  
32 of our genome. DSBs can be repaired by homologous recombination (HR), classical non-homologous  
33 end-joining (NHEJ) and alternative end-joining (A-EJ, also known as backup end joining, or  
34 microhomology-mediated end joining) [1-3]. HR is only available during S/G2 cell cycle phases when  
35 the sister chromatid is accessible and then used as a template. C-NHEJ acts throughout the entire cell  
36 cycle, sealing directly the broken ends and is the predominant repair pathway in mammalian cells [1,  
37 4]. A-EJ is often microhomology-mediated and more obvious in the absence of classical NHEJ [5].

38 NHEJ involves recognition of the DSBs by core Ku70/Ku80 heterodimer (Ku), which in turn  
39 recruits DNA-dependent protein kinase catalytic subunit (DNA-PKcs) to form a DNA-PK  
40 holoenzyme complex that protects free DNA ends. Assembly of DNA-PK triggers the  
41 autophosphorylation of DNA-PKcs, as well as DNA-PKcs-dependent phosphorylation of multiple  
42 other DNA repair factors [1]. Ku facilitates recruitment of accessory NHEJ factors, such as X-ray  
43 repair cross-complementing factor 4 (XRCC4)-like factor (XLF), a paralogue of XRCC4 and XLF

44 (PAXX), and a modulator of retrovirus infection (MRI). Ligation of the broken ends is performed by  
45 the core NHEJ factor DNA Ligase 4 (Lig4), which is stabilized by another core factor, XRCC4 [1-3].

46 Genetic inactivation of *Xrcc4* [6] or *Lig4* [7] in mice results in p53-dependent late embryonic  
47 lethality, which correlates with a massive apoptosis in the central nervous system (CNS) [8, 9].  
48 Although *Ku70<sup>-/-</sup>* and *Ku80<sup>-/-</sup>* knockout mice are viable, they present high levels of apoptosis in CNS  
49 and remarkable growth retardation [10, 11].

50 In mice, DNA-PKcs, PAXX and MRI are accessory NHEJ factors, while XLF can be considered  
51 as either core or accessory factor [2, 3]. *Dna-pkcs<sup>-/-</sup>* [12], *Xlf<sup>-/-</sup>* [13, 14], *Paxx<sup>-/-</sup>* [15-19] and *Mri<sup>-/-</sup>* [20, 21]  
52 knockout mice are viable, displaying normal growth, lifespan, and neuronal development. However,  
53 inactivation of DNA-PKcs kinase domain (*Dna-pkcs<sup>KD/KD</sup>*) leads to Ku- and p53-dependent embryonic  
54 lethality, which correlates with high levels of apoptosis in the CNS [22].

55 More recently, genetic interaction studies uncovered the importance of the accessory NHEJ  
56 factors in the development of immune and nervous systems and mouse development in general.  
57 Synthetic lethality was reported between *Xlf* and *Dna-pkcs* [19, 23, 24], then between *Xlf* and *Paxx* [2,  
58 15, 16, 18, 19], and finally between *Xlf* and *Mri* [2, 20]. These studies confirmed that functions of DNA-  
59 PKcs, PAXX, and MRI are partially compensated by XLF. However, the role of accessory NHEJ factors  
60 in early neurodevelopment remains unknown.

61 Here, using single and double knockout mouse models, we found that XLF, DNA-PKcs and  
62 PAXX are required to maintain pluripotency of neural stem cells, including aspects of self-renewal,  
63 proliferation, and differentiation to neurons and astrocytes.

## 64 2. Materials and Methods

### 65 2.1. Mice

66 All experimental procedures involving mice were performed according to the protocols  
67 approved by the Comparative Medicine Core Facility at Norwegian University of Science and  
68 Technology (NTNU, Norway). *Dna-pkcs<sup>+/-</sup>* [12], *Xlf<sup>+/-</sup>* [13], and *Paxx<sup>+/-</sup>* [17] mouse models were  
69 previously described.

### 70 2.2. Mouse genotyping

71 A conventional polymerase chain reaction (PCR) was used to determine the mouse genotypes.  
72 DNA was isolated from ear punches digested overnight at 56°C with 2 % proteinase K in DNA lysis  
73 solution containing 10 mM pH=9.0 Tris, 1 M KCl, 0.4 % NP-40 and 0.1 % Tween 20. Next, the samples  
74 were heat-treated for 30 minutes at 95°C. The PCR reactions were performed using *GoTaq@G2 Green*  
75 *Master Mix* (Promega, WI, USA; #M7823) or *Taq 2x Master Mix Kit* (New England Biolabs® Inc.,  
76 Ipswich, MA, USA; #M0270L) according to the manufacturer's instructions. Each reaction contained  
77 50 ng of DNA and 0.8 μM of indicated primers (Supplementary Table 5) in a final volume of 25 μL.  
78 The PCR product was revealed in a 0.7 % agarose gel.

### 79 2.3. Neural stem and progenitor cell cultures

80 Neural stem and progenitor cells (NSPCs) were cultured as free-floating aggregates, also known  
81 as neurospheres [21, 25]. Briefly, murine embryos were collected at embryonic day E15.5, the brains  
82 were isolated and the cerebellums were removed. Remaining brain parts were mechanically  
83 disrupted in proliferation medium, containing Dulbecco Modified Eagle Medium / Nutrient Mixture

84 F12 (DMEM/F12), supplemented with 1 % penicillin/streptomycin, 2 % B27 without vitamin A  
85 (Thermo Fischer Scientific, USA), 10 ng/mL EGF and 20 ng/mL bFGF. The neurospheres were formed  
86 and incubated at 37°C, 5 % CO<sub>2</sub> and 95 % humidity. The neurospheres were dissociated every seventh  
87 day using 0.25 % of Trypsin in EDTA, as previously described in [21, 25]. For more details, see also  
88 *Supplementary Materials and Methods*. The neurospheres from passages 3 to 10 were used in all the  
89 experiments.

#### 90 2.4. Proliferation assay

91 NSPCs proliferation rates were assayed using *PrestoBlue™ Cell Viability Assay* (Thermo Fisher  
92 Scientific, Waltham, MA, USA; A13261) following the manufacturer's protocol and [26]. Briefly,  
93 dissociated single NSPCs were loaded onto a 96-well-suspension plate at 8,000 cells/well in  
94 proliferation medium. *PrestoBlue™ reagent* was added at 10 % of the well volume at day 3, and  
95 incubated for 2 hours at 37°C, 5 % CO<sub>2</sub> and 95 % humidity. The proportion of live cells was estimated  
96 by measuring fluorescence intensity using FLUOstar Omega system (BMG Labtech, Germany).

#### 97 2.5. Self-renewal capacity assay

98 We followed the protocol described earlier [21]. Briefly, the capacity of neural stem cells to  
99 maintain their multipotency *ex vivo* was assessed by determining the number and two-dimensional  
100 size of neurospheres. Dissociated single NSPCs were plated onto 6-well suspension plates containing  
101 proliferation medium (day 0). At day 8, images of the entire wells were captured using the EVOS  
102 microscope (Invitrogen, USA). The pictures were analyzed using the *ImageJ* software (NIH, USA) to  
103 obtain the total number of neurospheres per well and size of spheres (pixels, px).

#### 104 2.6. Differentiation assay

105 Differentiation was induced in dissociated NSPCs, as described previously [21, 25]. Briefly,  
106 25,000 single NSPCs were cultured onto 48-well plates pre-coated with 30 µg/mL poly-D-lysine and  
107 2 µg/mL laminin, with differentiation medium containing NeuroBasal A medium (Thermo Fischer  
108 Scientific, USA) supplemented with 1 % penicillin/streptomycin, 2 % B27, 1 % GlutaMAX and  
109 10 ng/mL bFGF (day 0) (also see *Supplementary Materials and Methods*). On day 5, the differentiated  
110 cells were fixed with 4 % paraformaldehyde for 15 minutes at room temperature. Further, an  
111 immunostaining was performed using antibodies recognizing either the neuron-specific β-III tubulin  
112 (Tuj1) or the glial fibrillary acidic protein (GFAP) proteins, to determine neurons and astrocytes  
113 respectively after differentiation [21, 25]. Briefly, the cells were permeabilized with 0.1 % Triton X-100  
114 for 30 minutes, washed 3 times with PBS (Oxoid Limited, UK), and blocked with 1:2 dilution of  
115 blocking solution containing 10 % BSA (Sigma, USA), 10 % goat serum (Invitrogen, USA) and 0.1 %  
116 Triton X-100 (Sigma, USA) for an hour, and washed with PBS. Then, the cells were incubated with  
117 the indicated primary antibodies in 10 % blocking solution for one hour at room temperature and  
118 washed with PBS. Next, the cells were incubated for one hour with the secondary fluorescent marker-  
119 conjugated antibodies at room temperature and counterstained with 1 µg/mL of 4'6-diamidino-2-  
120 phenylindole (DAPI, *Molecular Probes, USA*). Images were collected using the *EVOS* microscope.  
121 Positively-stained cells were counted using *ImageJ* software and presented as a proportion of total  
122 cells normalized to WT control.

#### 123 2.7. Western blot

124 Western blots were performed using antibodies against XLF, PAXX, DNA-PKcs, and  $\beta$ -actin  
125 (*Supplementary Materials and Methods*) [17, 26, 27]. Neurospheres were collected and lysed with RIPA  
126 buffer (Sigma, USA) containing cOmplete™ EDTA-free Protease Inhibitor Cocktail (Roche, USA) and  
127 1 mM phenylmethanesulfonyl fluoride (PMSF, Sigma, USA). Protein concentrations were  
128 determined by Bradford assay (Biorad, USA). Further, 40  $\mu$ g of protein from each clone was analyzed  
129 by the SDS-PAGE gel. Proteins were transferred to the membranes using XCell II™ Blot Module  
130 (*ThermoFisher Scientific, USA*) at 4°C. Then, the membranes were blocked with 5 % milk in PBS with  
131 10 % Tween 20 (PBST) for one hour at room temperature. Primary antibodies were incubated  
132 overnight at 4°C, rinsed with PBST 3 times for 5 minutes and incubated with the secondary antibodies  
133 for one hour at room temperature. The blot was washed and incubated with SuperSignal™West  
134 Femto (Thermo Fischer Scientific, USA) to reveal the proteins with ChemiDoc™ Touch Imaging  
135 System (BioRad, USA).


### 136 2.8. Statistical analysis

137 To analyze the data, we pulled together two clones per genotype, representing an independent  
138 mouse embryo each, and performed three independent experiments with every clone. All the data  
139 shown were normalized to WT average levels. To find statistical differences among the genotypes,  
140 Kruskal-Wallis test with Dunn's multiple comparisons test, as a non-parametric alternative of one-  
141 way ANOVA, was used. The statistical analyses were performed using *GraphPad Prism 7.03* software  
142 (*GraphPad Prism, USA*) [21, 25].

## 143 3. Results

### 144 3.1. Impact of XLF, PAXX, and DNA-PKcs on proliferation and self-renewal capacity of neural stem and 145 progenitor cells

146 Single knockout of NHEJ genes *Xlf*, *Dna-pkcs* or *Paxx* results in viable fertile mice without  
147 detectable phenotypes in the CNS [12-18]. Contrary, combined inactivation of *Xlf* and *Dna-pkcs*, or  
148 *Xlf* and *Paxx* results in a synthetic lethality (Figure 1A) that correlates with severe apoptosis in the  
149 CNS [2, 15, 16, 18, 19, 23, 24]. To further investigate the impact of XLF, DNA-PKcs, and PAXX on the  
150 nervous system development, we enriched NSPCs by generating neurosphere cultures from WT, *Xlf*  
151 <sup>-/-</sup>, *Paxx*<sup>-/-</sup>, *Dna-pkcs*<sup>-/-</sup>, *Xlf*<sup>-/-</sup>*Paxx*<sup>-/-</sup>, and *Xlf*<sup>-/-</sup>*Dna-pkcs*<sup>-/-</sup> mouse embryos and characterized cell  
152 proliferation, self-renewal, and neural differentiation capacity (Figures 1-3).



153

154 **Figure 1. Workflow of the neurosphere-based experiments.** (A) Synthetic lethality between *Xlf* and *Paxx* in  
 155 mice. The proportion of live-born mice from *Xlf<sup>-/-</sup>Paxx<sup>+/-</sup>* parents. No *Xlf<sup>-/-</sup>Paxx<sup>-/-</sup>* double knockout live-born mice  
 156 were observed out of 43 pups analyzed. (B) Fifteen-day-old *Xlf<sup>-/-</sup>Paxx<sup>+/-</sup>* mouse embryos are alive. The proportion  
 157 of genotypes from *Xlf<sup>-/-</sup>Paxx<sup>+/-</sup>* parents. Three E15.5 *Xlf<sup>-/-</sup>Paxx<sup>-/-</sup>* embryos were detected out of 42 analyzed. (C)  
 158 Schematic view of the experiment. Embryos were collected at day E15.5 and NSPCs were isolated from the  
 159 embryonic brains. Single NSPCs formed neurospheres in cell culture. Every seventh days the neurospheres were  
 160 treated with trypsin to obtain NSPCs used to perform the proliferation, self-renewal and differentiation  
 161 experiments.


162

163 To obtain *Xlf<sup>-/-</sup>Paxx<sup>-/-</sup>* embryos, we intercrossed *Xlf<sup>-/-</sup>Paxx<sup>+/-</sup>* mice. As we observed previously [2,  
 164 19], no live-born *Xlf<sup>-/-</sup>Paxx<sup>-/-</sup>* pups were detected (0), while we recorded *Xlf<sup>-/-</sup>Paxx<sup>+/+</sup>* (16) and *Xlf<sup>-/-</sup>Paxx<sup>+/-</sup>*  
 165 (27) live-born mice (Figure 1A). By analyzing 15.5E embryos in the same breedings, we detected *Xlf<sup>-/-</sup>*  
 166 *Paxx<sup>-/-</sup>* (3), *Xlf<sup>-/-</sup>Paxx<sup>+/+</sup>* (8) and *Xlf<sup>-/-</sup>Paxx<sup>+/-</sup>* (31) mice, which were later used for the neurosphere  
 167 generation and characterization. *Xlf<sup>-/-</sup>Dna-pkcs<sup>-/-</sup>* mice were described earlier [19]. Briefly, by breeding  
 168 *Xlf<sup>-/-</sup>Dna-pkcs<sup>+/-</sup>* mice, we obtained no adult *Xlf<sup>-/-</sup>Dna-pkcs<sup>-/-</sup>* mice (0), while there were *Xlf<sup>-/-</sup>Dna-pkcs<sup>+/+</sup>*  
 169 (35) and *Xlf<sup>-/-</sup>Dna-pkcs<sup>+/-</sup>* (54) mice at day P30. However, live born *Xlf<sup>-/-</sup>Dna-pkcs<sup>-/-</sup>* mice were detected  
 170 at days P1-2, in line with our previous observations [19, 23, 24].

171

172 By analyzing the neurosphere cultures, we observed that the average proliferation rates of *Xlf<sup>-/-</sup>*  
 173 *Paxx<sup>-/-</sup>* and *Xlf<sup>-/-</sup>Dna-pkcs<sup>-/-</sup>* double knockout neurospheres were reduced when compared to WT and  
 174 single deficient *Xlf<sup>-/-</sup>*, *Dna-pkcs<sup>-/-</sup>* or *Paxx<sup>-/-</sup>* neurospheres (Figure 2B). To quantify the self-renewal  
 175 capacity of neurospheres, we plated 10,000 NSPCs and counted the formed neurospheres at day 8 in  
 176 culture (Figure 2C). Inactivation of *Xlf* resulted in 20% reduction and inactivation of *Paxx* resulted in  
 a 40% reduction of neurosphere count when compared to WT controls. Combined inactivation of *Xlf*

177 and *Paxx* resulted in about 80% reduction of neurosphere count, further highlighting the severe  
 178 neurological phenotype of *Xlf<sup>-/-</sup>Paxx<sup>-/-</sup>* mice observed *in vivo* [15, 16, 18]. Surprisingly, inactivation of  
 179 *Dna-pkcs* resulted in a higher number of viable neurospheres, although of smaller size. Combined  
 180 inactivation of *Xlf* and *Dna-pkcs* resulted in neurosphere count similar to WT controls. We concluded  
 181 that inactivation of *Xlf* and *Paxx* affected self-renewal capacity and viability of NSPCs (Figure 2C).




182  
 183 **Figure 2. Proliferation and self-renewal capacity of NSPC.** (A) Western blot analysis revealed no signal  
 184 corresponding to XLF in *Xlf<sup>-/-</sup>*, *Xlf<sup>-/-</sup>Paxx<sup>-/-</sup>* and *Xlf<sup>-/-</sup>Dna-pkcs<sup>-/-</sup>* NSPC; no signal corresponding to PAXX in *Paxx<sup>-/-</sup>*  
 185 and *Xlf<sup>-/-</sup>Paxx<sup>-/-</sup>* NSPC; no signal corresponding to DNA-PKcs in *Dna-pkcs<sup>-/-</sup>* and *Xlf<sup>-/-</sup>Dna-pkcs<sup>-/-</sup>* NSPC;  $\beta$ -actin was  
 186 used as a loading control. (B) Amount of neurospheres of indicated genotypes after 48 hours of proliferation,  
 187 expressed as fluorescence units and normalized to WT controls. Summary of six replicates per two clones, where  
 188 each clone represents an independent mouse embryo; and three independent experiments (total n=36). The  
 189 horizontal bars represent the average. Count, n (C) and size, pixels (px) (D) of neurospheres of indicated  
 190 genotypes after 8 days in culture. Summary of two replicates per clone, two clones per genotype representing  
 191 an independent mouse embryos each; three independent experiments (n=12). The horizontal bars represent the  
 192 average values.

193  
 194 To determine neurosphere growth rate, we used an alternative quantification based on the image  
 195 size in pixels (px) (Figure 2D). Inactivation of *Xlf*, *Dna-pkcs*, or both *Xlf/Dna-pkcs*, resulted in  
 196 neurospheres with 30% to 50% reduction in size when compared to WT controls. Inactivation of *Paxx*  
 197 did not affect the size of neurospheres in WT and *Xlf*-deficient backgrounds (Figure 2D). We  
 198 concluded that both XLF and DNA-PKcs support growth of NSPCs in neurospheres.

199 3.2. Impact of XLF, PAXX, and DNA-PKcs on differentiation capacity of neural stem and progenitor cells

200 To determine whether XLF, PAXX, and DNA-PKcs affect neural differentiation capacity, single  
201 NSPCs (25,000 cells) were plated on pre-coated 48-well plates and cultured with differentiation  
202 medium for 5 days. Neuronal and glial lineages were identified by immunolabeling using markers  
203 for early neurons (Tuj1), and for astrocytes (GFAP). Inactivation of *Xlf*, *Paxx* or *Dna-pkcs*, and  
204 combined inactivation of *Xlf/Paxx* did not affect early neuronal differentiation based on average  
205 proportions of Tuj1-positive cells (Figure 3A). Combined inactivation of *Xlf* and *Dna-pkcs*, however,  
206 resulted in two-fold reduced neurodifferentiation capacity of NSPCs (Figure 3A,C). The proportion  
207 of GFAP-positive glial lineage cells increased, although not significantly, when NSPCs were lacking  
208 either XLF or PAXX, or both XLF and PAXX (Figure 3B,D).



209  
210 **Figure 3. Differentiation of neural progenitors to neurons and astrocytes.** (A) Proportion of Tuj1<sup>+</sup> early neurons  
211 and (B) GFAP<sup>+</sup> astrocytes following five days of differentiation from NSPC of indicated genotypes, and  
212 normalized by WT controls. Average of two replicates per clone, where two clones represent an independent  
213 mouse embryo, and three independent experiments (n=12). (C, D) Examples of the immunostaining using  
214 antibodies against Tuj1 and GFAP, as indicated. Tuj1<sup>+</sup> cells are in green (C). GFAP<sup>+</sup> cells are in red (D). DNA  
215 was visualized with DAPI (blue). Negative controls were performed without adding the primary antibodies  
216 (bottom).

217  
218  
219

Overall, XLF possesses functional redundancy with PAXX during the NSPC self-renewal, and with DNA-PKcs during cell growth and neuronal differentiation (Figures 2-3).

## 220 4. Discussion

221 Here, we demonstrated that NHEJ factors XLF, PAXX and DNA-PKcs support cellular  
222 proliferation during early mammalian neurogenesis, when the proliferation rate is high and the  
223 likelihood of DNA damages arising from DNA replication machinery is increased. In *Xrcc4<sup>-/-</sup>*, *Lig4<sup>-/-</sup>*,  
224 *Xlf<sup>-/-</sup>Paxx<sup>-/-</sup>* and *Xlf<sup>-/-</sup>Dna-pkcs<sup>-/-</sup>* mice NHEJ is ablated. Therefore, to avoid increased genomic instability  
225 during proliferation, developing neurons undergo programmed cell death via the p53-dependent  
226 pathway [8, 9, 15, 16, 18, 19, 23, 24].

227 Although mice lacking XLF possess normal CNS development [13, 14], human patients with  
228 mutations in *Cernunnos/XLF* gene suffer from neurological defects, in addition to immunodeficiency  
229 [28, 29]. The difference between human and murine phenotypes might be related to the fact that  
230 multiple NHEJ and DNA damage response factors, e.g. ATM, H2AX, MDC1, 53BP1, DNA-PKcs,  
231 PAXX, MRI, RAG2, partially compensate for the lack of XLF in mice [1, 2, 15, 16, 18-20, 23, 24, 30-37].  
232 In other words, XLF compensates for the lack of multiple factors, including DNA-PKcs and PAXX.  
233 Our recent observations revealed that DNA-PKcs and PAXX are likely in the same sub-pathway of  
234 NHEJ, because *Dna-pkcs<sup>-/-</sup>Paxx<sup>-/-</sup>* mice do not possess any additional phenotype when compared to  
235 the *Dna-pkcs<sup>-/-</sup>* or *Paxx<sup>-/-</sup>* mice [19, 26]. In particular, human HAP1 cell lines lacking both DNA-  
236 PKcs/PAXX possess the same levels of genomic instability and sensitivity to DNA damage-inducing  
237 agents etoposide, doxorubicine and bleomycin as DNA-PKcs-deficient ones [19, 26]. Moreover, mice  
238 lacking both DNA-PKcs and PAXX are live-born, fertile and do not show any additional phenotype  
239 when compared to immunodeficient *Dna-pkcs<sup>-/-</sup>* knockout mice [19].

240 Neurospheres lacking both XLF and DNA-PKcs displayed reduced capacity to differentiate  
241 towards neurons that partially explains the severe phenotype of *Xlf<sup>-/-</sup>Dna-pkcs<sup>-/-</sup>* mice [2, 19, 23, 24].  
242 Differently, lack of XLF or PAXX results in a moderate increase in the capacity of neural progenitors  
243 to develop into astrocytes. Double knockout *Xlf<sup>-/-</sup>Paxx<sup>-/-</sup>* and *Xlf<sup>-/-</sup>Dna-pkcs<sup>-/-</sup>* neural progenitors possess  
244 reduced proliferation capacity (Figure 2B), although due to different reasons. While lack of XLF and  
245 PAXX results in lower count of neurospheres likely due to increased rate of cell death (Figure 2C),  
246 combined inactivation of *Xlf* and *Dna-pkcs* results in smaller neurospheres (Figure 2D), which can be  
247 explained, as one option, by cell cycle arrest due to increased levels of genomic instability [2, 3, 18].  
248 Further analyzes of early neurodevelopment *in vivo* and *in vitro* will help to reveal new insights  
249 regarding the role of NHEJ factors in neurodevelopment. Double and multiple-knockout genetic  
250 models will facilitate these studies unravelling functional redundancy between the DNA repair  
251 factors.

## 252 5. Conclusions

253 XLF is functional redundancy with PAXX during the neuronal stem and progenitor cells self-  
254 renewal, and with DNA-PKcs during cell growth and neuronal differentiation. The NHEJ factors  
255 DNA-PKcs, PAXX and XLF are required for an efficient early stage development of neuronal stem  
256 and progenitor cells in mice. Additional NHEJ factors such as Mri/Cyren, Ku70, Ku80, XRCC4 and  
257 Lig4, as well as multiple ATM-dependent DDR factors might have similar function in  
258 neurodevelopment.

259 **Supplementary Materials:** The following are available online at [www.mdpi.com/xxx/s1](http://www.mdpi.com/xxx/s1), Table S1: Commercial  
260 reagents; Table S2: Antibodies; Table S3: Equipment and Software; Table S4: Solutions and cell culture media;  
261 Table S5: Genotyping primers.

262 **Author Contributions:** Conceptualization, R.G.F. and V.O.; methodology, R.G.F. and V.O.; software, R.G.F. and  
263 V.O.; validation, R.G.F.; formal analysis, R.G.F.; investigation, R.G.F. and V.O.; resources, V.O.; data curation,



264 R.G.F.; writing—original draft preparation, R.G.F. and V.O.; writing—review and editing, R.G.F. and V.O.;  
265 visualization, R.G.F.; supervision, V.O.; project administration, V.O.; funding acquisition, V.O. Both authors  
266 have read and agreed to the published version of the manuscript.

267 **Funding:** This research was funded by the following grants: The Research Council of Norway (#249774, #270491  
268 and #291217); the Norwegian Cancer Society (#182355); The Health Authority of Central Norway (#13477 and  
269 #38811); The Outstanding Academic Fellow Program at NTNU 2017-2021. VO was a recipient of Karolinska  
270 Institutet Stiftelser och Fonder #2020-02155 research grant.

271 **Acknowledgments:** We thank Wei Wang for fruitful discussions during the project development.

272 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the  
273 study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to  
274 publish the results.

## 275 References

- 276 1. Kumar, V., F.W. Alt, and V. Oksenyck, *Functional overlaps between XLF and the ATM-dependent DNA*  
277 *double strand break response*. DNA Repair (Amst), 2014. **16**: p. 11-22.
- 278 2. Castaneda-Zegarra, S., et al., *Genetic interaction between the non-homologous end joining factors during B*  
279 *and T lymphocyte development: in vivo mouse models*. Scand J Immunol, 2020: p. e12936.
- 280 3. Wang, X.S., B.J. Lee, and S. Zha, *The recent advances in non-homologous end-joining through the lens of*  
281 *lymphocyte development*. DNA Repair (Amst), 2020. **94**: p. 102874.
- 282 4. Pannunzio, N.R., G. Watanabe, and M.R. Lieber, *Nonhomologous DNA end-joining for repair of DNA*  
283 *double-strand breaks*. J Biol Chem, 2018. **293**(27): p. 10512-10523.
- 284 5. Boboila, C., et al., *Robust chromosomal DNA repair via alternative end-joining in the absence of X-ray repair*  
285 *cross-complementing protein 1 (XRCC1)*. Proc Natl Acad Sci U S A, 2012. **109**(7): p. 2473-8.
- 286 6. Gao, Y., et al., *A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis*. Cell, 1998.  
287 **95**(7): p. 891-902.
- 288 7. Frank, K.M., et al., *Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV*.  
289 Nature, 1998. **396**(6707): p. 173-7.
- 290 8. Frank, K.M., et al., *DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via*  
291 *the p53 pathway*. Mol Cell, 2000. **5**(6): p. 993-1002.
- 292 9. Gao, Y., et al., *Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and*  
293 *development*. Nature, 2000. **404**(6780): p. 897-900.
- 294 10. Gu, Y., et al., *Growth retardation and leaky SCID phenotype of Ku70-deficient mice*. Immunity, 1997. **7**(5): p.  
295 653-65.
- 296 11. Nussenzweig, A., et al., *Requirement for Ku80 in growth and immunoglobulin V(D)J recombination*. Nature,  
297 1996. **382**(6591): p. 551-5.
- 298 12. Gao, Y., et al., *A targeted DNA-PKcs-null mutation reveals DNA-PK-independent functions for KU in V(D)J*  
299 *recombination*. Immunity, 1998. **9**(3): p. 367-76.
- 300 13. Li, G., et al., *Lymphocyte-specific compensation for XLF/cernunnos end-joining functions in V(D)J*  
301 *recombination*. Mol Cell, 2008. **31**(5): p. 631-40.
- 302 14. Vera, G., et al., *Cernunnos deficiency reduces thymocyte life span and alters the T cell repertoire in mice and*  
303 *humans*. Mol Cell Biol, 2013. **33**(4): p. 701-11.
- 304 15. Abramowski, V., et al., *PAXX and Xlf interplay revealed by impaired CNS development and immunodeficiency*  
305 *of double KO mice*. Cell Death Differ, 2018. **25**(2): p. 444-452.
- 306 16. Balmus, G., et al., *Synthetic lethality between PAXX and XLF in mammalian development*. Genes Dev, 2016.  
307 **30**(19): p. 2152-2157.

- 308 17. Gago-Fuentes, R., et al., *Normal development of mice lacking PAXX, the paralogue of XRCC4 and XLF*. FEBS  
309 Open Bio, 2018. 8(3): p. 426-434.
- 310 18. Liu, X., et al., *PAXX promotes KU accumulation at DNA breaks and is essential for end-joining in XLF-deficient*  
311 *mice*. Nat Commun, 2017. 8: p. 13816.
- 312 19. Castaneda-Zegarra, S., et al., *Synthetic lethality between DNA repair factors Xlf and Paxx is rescued by*  
313 *inactivation of Trp53*. DNA Repair (Amst), 2019. 73: p. 164-169.
- 314 20. Hung, P.J., et al., *MRI Is a DNA Damage Response Adaptor during Classical Non-homologous End Joining*.  
315 Mol Cell, 2018. 71(2): p. 332-342 e8.
- 316 21. Castaneda-Zegarra, S., et al., *Generation of a Mouse Model Lacking the Non-Homologous End-Joining Factor*  
317 *Mri/Cyren*. Biomolecules, 2019. 9(12).
- 318 22. Jiang, W., et al., *Differential phosphorylation of DNA-PKcs regulates the interplay between end-processing and*  
319 *end-ligation during nonhomologous end-joining*. Mol Cell, 2015. 58(1): p. 172-85.
- 320 23. Oksenyich, V., et al., *Functional redundancy between the XLF and DNA-PKcs DNA repair factors in V(D)J*  
321 *recombination and nonhomologous DNA end joining*. Proc Natl Acad Sci U S A, 2013. 110(6): p. 2234-9.
- 322 24. Xing, M., et al., *Synthetic lethality between murine DNA repair factors XLF and DNA-PKcs is rescued by*  
323 *inactivation of Ku70*. DNA Repair (Amst), 2017. 57: p. 133-138.
- 324 25. Wang, W., et al., *Mitochondrial DNA integrity is essential for mitochondrial maturation during differentiation*  
325 *of neural stem cells*. Stem Cells, 2010. 28(12): p. 2195-204.
- 326 26. Xing, M. and V. Oksenyich, *Genetic interaction between DNA repair factors PAXX, XLF, XRCC4 and DNA-*  
327 *PKcs in human cells*. FEBS Open Bio, 2019. 9(7): p. 1315-1326.
- 328 27. Dewan, A., et al., *Robust DNA repair in PAXX-deficient mammalian cells*. FEBS Open Bio, 2018. 8(3): p.  
329 442-448.
- 330